<DOC>
	<DOC>NCT00004938</DOC>
	<brief_summary>OBJECTIVE: I. Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral sporotrichosis.</brief_summary>
	<brief_title>Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients are treated with daily oral fluconazole for up to 24 months. Follow-up continues for at least 1 year.</detailed_description>
	<mesh_term>Sporotrichosis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Presumptive evidence of sporotrichosis Cultureproven sporotrichosis determined on study Relapsing disease following antifungal therapy eligible if culture positive for Sporothrix schenckii prior to entry No lifethreatening disease No central nervous system sporotrichosis Prior/Concurrent Therapy No concurrent drugs known to react with fluconazole No more than 3 days of systemic antifungals for current sporotrichosis episode Patient Characteristics Hepatic: Liver function tests no greater than 5 times normal Other: No HIV infection No pregnant or nursing women</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>fungal infection</keyword>
	<keyword>rare disease</keyword>
	<keyword>sporotrichosis</keyword>
</DOC>